Cefepime i.v.

Phase 2Small molecule

Cefepime i.v. is one of 2 small molecule programs targeting Complicated Urinary Tract Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Complicated Urinary Tract InfectionRecruiting

Complicated Urinary Tract InfectionPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Complicated Urinary Tract Infection

#DrugCompanyPhaseTrials

Maxipime

Pfizer

Phase 2

1 2

Cefepime i.v.

AAllecra

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Complicated Urinary Tract Infection

NCT05826990

Clinical

Trials by Indication[1]

Phase 21 trial

Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI

Completed·AAllecra·Phase 2·NCT03680612·45 enrolled

Tics1 trial

Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)

Completed·AAllecra·Phase 1·NCT03680378·19 enrolled

Complicated Urinary Tract Infection1 trial

Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI

Recruiting·AAllecra·Phase 2·NCT05826990·40 enrolled

Unspecified1 trial

Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers

Completed·AAllecra·Phase 1·NCT03685084·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Cefepime i.v.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cefepime i.v. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cefepime i.v.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allecra company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAllecra

Cefepime i.v.

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Phase 21 trial

Tics1 trial

Complicated Urinary Tract Infection1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News